San Antonio Breast Cancer Symposium
The company has faced some early hurdles in joining competitors in the colorectal cancer space but believes it can claim first mover status in early breast cancer.
Myriad Genetics Generates More Data on Ability of PRS to Identify Who Will Develop Breast Cancer
Premium
In a validation study presented at SABCS, Myriad evaluated how well breast cancer risk assessments made with a clinco-genomic risk score aligned with observed incidence.
Investigators presented data from a meta-analysis that suggests the firm's POLAR gene expression test can identify patients unlikely to benefit from radiation.
Biocept to Refocus CNSide Assay Plans After FDA Feedback Suggests Targeting Narrower Indications
Premium
The company failed in its first bid for breakthrough device designation but has now split out new specific indications for which it is building more persuasive utility data.
SABCS Studies Show Promise of ctDNA Analysis in Individualizing CDK4/6 Inhibitor, Endocrine Therapy
Premium
Researchers investigated the potential of liquid biopsy testing to help patients avoid endocrine resistance in the PADA-1 trial and identify best responders in the BioltaLEE trial.